Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction

20260 citationsJournal Articlegreen Open Access

Authors

Darius Bordbar · Massachusetts Eye and Ear Infirmary

Ali Mukhtar · Baylor College of Medicine

Asad Loya · Associated Retinal Consultants

Amer F. Alsoudi · Associated Retinal Consultants

Jawad Muayad · Texas A&M University

Muhammad Z. Chauhan · University of Arkansas for Medical Sciences

Nimesh A. Patel

Abstract

Results of this cohort study reveal that peri-CVE anti-VEGF was not associated with increased mortality or morbidity. Outcomes did not differ among commonly used agents, supporting the safety of continuing intravitreal anti-VEGF therapy without modification during the peri-CVE period.

Topics & Keywords

Retinal Diseases and Treatments Corneal surgery and disorders Ocular Diseases and Behçet’s Syndrome

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Ophthalmology

DOI: 10.1001/jamaophthalmol.2026.0460

Field-Weighted Citation Impact: 0.00